Abstract
Clear cell tumor of borderline malignancy has been reported to account for 5 to 8% of all clear cell neoplasms, and <1% of borderline malignancies of the ovary. Borderline clear cell fibroadenoma with or without microinvasion mostly occurs in women with middle age, and the presenting symptoms associated with this tumor are non-specific. The clinico-pathologic features of borderline clear cell fibroadenoma are not well known because of its rarity. Furthermore, there is no consensus for treating the disease. Thus, we report a case of borderline clear cell fibroadenoma presenting as ovarian fibroadenoma with a review of literature.
References
1. Ryu SY, Park SI, Nam BH, et al. Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol. 2009. 20:1032–1036.
2. Yamamoto S, Tsuda H, Takano M, Hase K, Tamai S, Matsubara O. Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway. J Pathol. 2008. 216:103–110.
3. Bell DA, Scully RE. Benign and borderline clear cell adenofibromas of the ovary. Cancer. 1985. 56:2922–2931.
4. Pasaoglu O, Ciftci E, Tel N, Ozalp S, Acikalin MF. Benign clear cell adenofibroma of the ovary. A case report with literature review. Gynecol Obstet Invest. 2007. 64:36–39.
5. Schiller W, Rilke F, Degna AT. Parvilocular cystomas of the ovary; report of two cases. Obstet Gynecol. 1957. 10:28–33.
6. Roth LM, Langley FA, Fox H, Wheeler JE, Czernobilsky B. Ovarian clear cell adenofibromatous tumors. Benign, of low malignant potential, and associated with invasive clear cell carcinoma. Cancer. 1984. 53:1156–1163.
7. Kao GF, Norris HJ. Unusual cystadenofibromas: endometrioid, mucinous, and clear cell types. Obstet Gynecol. 1979. 54:729–736.
8. Yamamoto S, Tsuda H, Suzuki K, Takano M, Tamai S, Matsubara O. An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway. Virchows Arch. 2009. 455:261–270.
9. Randrianjafisamindrakotroka NS, Gasser B, Philippe E. The malignant potential of adenofibroma and cystadenofibroma of the ovary and mesovarium. 118 cases including 13 proliferative and 5 carcinomatous. J Gynecol Obstet Biol Reprod (Paris). 1993. 22:33–38.
10. Veras E, Mao TL, Ayhan A, Ueda S, Lai H, Hayran M, et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol. 2009. 33:844–853.
11. Sugiyama T, Nishida T, Kataoka A, Okura N, Iwanaga S, Yakushiji M. A pregnant woman with clear cell adenocarcinoma of the ovary arising from endometriosis and with benign and borderline adenofibroma of the clear cell and endometrioid types. Eur J Obstet Gynecol Reprod Biol. 1997. 72:47–50.
12. Marret H, Tranquart F, Sauget S, Lansac J. Sonographic diagnosis of ovarian tumors: pre-operative Doppler evaluation. J Radiol. 2003. 84:1725–1731.
13. Coumbos A, Sehouli J, Chekerov R, Schaedel D, Oskay-Oezcelik G, Lichtenegger W, et al. Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany. Br J Cancer. 2009. 100:1731–1738.
14. Kokawa K, Mikami Y, Sakata H, Oki N, Tanakas T, Yamazaki M, et al. Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years' experience in the Kinki District of Japan (1990-2006). Eur J Gynaecol Oncol. 2009. 30:155–161.
15. Rettenmaier MA, Lopez K, Abaid LN, Brown JV 3rd, Micha JP, Goldstein BH. Borderline ovarian tumors and extended patient follow-up: an individual institution's experience. J Surg Oncol. 2010. 101:18–21.